TACR1 and Ocular pain: The systemic route of administration and bioavailability of the drug at target sites, the brain and spine, and different distribution of NK1R in different tissues could all contribute to the debate on NK1R analgesic efficacy.38 Most recently, there has been a case series report of effective treatment of 3 patients with neuropathic eye pain of different etiologies by NK1R antagonists.77 Neurokinin-1 receptor antagonists continue being rigorously investigated for a variety of indications including pain, inflammation, itching, and others (ClinicalTrials.gov).